TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

PRESENTATION OF CLINICAL DATA ANALYSIS OF TINENGOTINIB MONOTHERAPY IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA AT 2026 ASCO GI

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company completed the poster presentation at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) to discuss the clinical data analysis of its core product tinengotinib monotherapy in patients with advanced cholangiocarcinoma (CCA).

Title: Phase II Study of Tinengotinib in Advanced Cholangiocarcinoma: Analysis of Molecular Response and Resistance Mechanisms

Form of Presentation: Poster

Poster Number: Bd D9

Presentation Time**:** January 10, 2026, 3:30-5:00 AM (Beijing Time) (January 9, 2026, 11:30-1:00 PM (PST))

FGFR inhibitors have an established role in treating FGFR2-altered CCA. Tinengotinib, a novel FGFR inhibitor, has shown promising activity of overcoming acquired resistance to prior FGFR inhibitor. In this poster presentation, the Company presents circulating tumour DNA (ctDNA) biomarker analyses evaluating tinengotinib's ability to treat CCA patients with FGFR2 fusions with primary FGFR inhibitor resistance, or FGFR2 fusions with acquired FGFR inhibitor resistance, or other FGFR alterations, or wild-type FGFR.

Genomic alterations in patients' ctDNA were assessed in the poster presentation. Correlative analyses of efficacy in patient subgroups based on ctDNA mutational status were performed. These results support further investigation with expanded biomarker sampling in an ongoing Phase III clinical trial.

Disclaimer: This article serves as a press release by the Company to disclose the Company's latest developments. It is not intended as a product promotion advertisement and does not constitute the Company's investment advice. Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant product will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, January 12, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.